Vancouver, B.C. – April 27, 2018 – Medipure Pharmaceuticals Inc., a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, today announced the appointment of industry veteran Dr. Safwat Rabea to its scientific team as Research Scientist – Medicinal Chemistry.

We are so excited to have recently opened a 3,750 square foot research lab on the BCIT campus in Burnaby. This lab is crucial in our quest to help patients worldwide.

As a company we are committed to developing economical non-addictive prescription medications derived from specific cannabinoid molecules. Our core products target key disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis and dermatology. This lab is our first step in fulfilling our dreams.

Medipure Pharmaceuticals has established itself as a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications through state of the art research and development. Medipure is wrapping up an extremely successful 2017 with highlights that include achieving new research milestones, developing new strategic relationships, adding renowned industry leaders to the team, and much more.

Vancouver, BC - November 28, 2017 - Medipure Pharmaceuticals, a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, is pleased to announce the addition of Dr. Gerald Zamponi to the company’s Scientific Advisory Board.